The Latest Breaking News from Eli Lilly

Netflix is among the stocks with most bullish analyst ratings. (Netflix)

Trump tariff news: President Trump's latest tariffs took effect Wednesday while China stepped up retaliation. Treasury yields are worrisome. Walmart and Delta Air pulled some guidance, citing tariff uncertainty.

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several disappointing trial results. However, analysts remain optimistic about the shares, forecasting a potential price upside of up to 60% over the next 12 months.

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling

The company behind the drug donanemab said it will ask regulators to reconsider the decision.

Potential US tariffs on pharmaceuticals could set off a ripple effect that extends far beyond the immediate price hikes, as both the US and Europe heavily rely on each other.

See what analysts' price targets say about the prospects of these three stocks flirting with the $1 trillion valuation mark.

The World Health Organization states that there were around 830 million people living with diabetes in 2022. More than half of them weren't taking diabetes medications, including insulin, likely due to access and cost issues.

Eli Lilly shows improving price performance, earning an upgrade to its IBD Relative Strength Rating